PortfoliosLab logo
United Therapeutics Corporation (UTHR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US91307C1027

CUSIP

91307C102

IPO Date

Jun 17, 1999

Highlights

Market Cap

$13.09B

EPS (TTM)

$24.63

PE Ratio

11.83

PEG Ratio

1.43

Total Revenue (TTM)

$2.20B

Gross Profit (TTM)

$1.96B

EBITDA (TTM)

$1.18B

Year Range

$233.31 - $417.82

Target Price

$388.02

Short %

5.02%

Short Ratio

3.34

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in United Therapeutics Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%1,000.00%2,000.00%3,000.00%4,000.00%5,000.00%6,000.00%7,000.00%NovemberDecember2025FebruaryMarchApril
4,681.58%
312.36%
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Returns By Period

United Therapeutics Corporation had a return of -17.42% year-to-date (YTD) and 24.60% in the last 12 months. Over the past 10 years, United Therapeutics Corporation had an annualized return of 5.89%, while the S&P 500 had an annualized return of 10.15%, indicating that United Therapeutics Corporation did not perform as well as the benchmark.


UTHR

YTD

-17.42%

1M

-5.40%

6M

-16.43%

1Y

24.60%

5Y*

21.24%

10Y*

5.89%

^GSPC (Benchmark)

YTD

-6.06%

1M

-2.95%

6M

-4.87%

1Y

8.34%

5Y*

13.98%

10Y*

10.15%

*Annualized

Monthly Returns

The table below presents the monthly returns of UTHR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-0.47%-8.86%-3.68%-5.48%-17.42%
2024-2.32%5.06%1.81%2.01%17.41%15.78%-1.65%16.04%-1.43%4.36%-0.93%-4.76%60.46%
2023-5.37%-6.51%-8.97%2.75%-8.86%5.25%9.95%-7.56%0.67%-1.33%7.69%-8.38%-20.93%
2022-6.58%-17.67%7.95%-1.03%29.73%2.30%-1.94%-1.93%-7.61%10.10%21.41%-0.64%28.70%
20217.93%2.05%0.05%20.50%-7.77%-3.49%1.40%18.11%-14.10%3.35%-0.66%14.03%42.35%
202010.89%5.42%-7.90%15.54%7.66%2.59%-7.88%-4.05%-5.57%32.90%-1.18%14.44%72.33%
20195.90%9.50%-7.06%-12.61%-18.13%-7.04%1.51%4.19%-3.40%12.65%2.69%-4.53%-19.12%
2018-12.81%-10.19%-3.01%-2.00%-3.21%6.16%8.63%0.07%3.98%-13.31%6.53%-7.79%-26.39%
201714.08%-9.72%-8.35%-7.15%-3.83%7.31%-1.03%1.87%-10.41%1.19%9.61%13.82%3.15%
2016-21.35%-1.01%-8.62%-5.59%13.18%-11.04%14.25%1.05%-3.43%1.69%4.61%14.19%-8.42%
20158.99%9.86%11.21%-7.39%15.05%-5.32%-2.64%-11.07%-12.87%11.73%4.09%2.61%20.94%
2014-9.25%-1.17%-7.29%6.36%-4.27%-7.57%2.77%29.57%9.18%1.80%1.22%-2.32%14.51%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 75, UTHR is among the top 25% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of UTHR is 7575
Overall Rank
The Sharpe Ratio Rank of UTHR is 7979
Sharpe Ratio Rank
The Sortino Ratio Rank of UTHR is 7272
Sortino Ratio Rank
The Omega Ratio Rank of UTHR is 7272
Omega Ratio Rank
The Calmar Ratio Rank of UTHR is 8080
Calmar Ratio Rank
The Martin Ratio Rank of UTHR is 7373
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for UTHR, currently valued at 0.75, compared to the broader market-2.00-1.000.001.002.003.00
UTHR: 0.75
^GSPC: 0.46
The chart of Sortino ratio for UTHR, currently valued at 1.17, compared to the broader market-6.00-4.00-2.000.002.004.00
UTHR: 1.17
^GSPC: 0.77
The chart of Omega ratio for UTHR, currently valued at 1.17, compared to the broader market0.501.001.502.00
UTHR: 1.17
^GSPC: 1.11
The chart of Calmar ratio for UTHR, currently valued at 0.76, compared to the broader market0.001.002.003.004.005.00
UTHR: 0.76
^GSPC: 0.47
The chart of Martin ratio for UTHR, currently valued at 1.97, compared to the broader market-5.000.005.0010.0015.0020.00
UTHR: 1.97
^GSPC: 1.94

The current United Therapeutics Corporation Sharpe ratio is 0.75. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of United Therapeutics Corporation with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2025FebruaryMarchApril
0.75
0.46
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


United Therapeutics Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-35.00%-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2025FebruaryMarchApril
-28.93%
-10.07%
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the United Therapeutics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the United Therapeutics Corporation was 93.18%, occurring on Dec 10, 2001. Recovery took 2282 trading sessions.

The current United Therapeutics Corporation drawdown is 28.93%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.18%Jul 13, 2000352Dec 10, 20012282Jan 3, 20112634
-60.3%Apr 24, 20151068Jul 22, 2019428Apr 1, 20211496
-60.2%Feb 28, 200036Apr 17, 200051Jun 29, 200087
-47.37%Apr 28, 2011110Oct 3, 2011451Jul 22, 2013561
-31.98%Nov 11, 2024103Apr 10, 2025

Volatility

Volatility Chart

The current United Therapeutics Corporation volatility is 10.59%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%NovemberDecember2025FebruaryMarchApril
10.59%
14.23%
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of United Therapeutics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how United Therapeutics Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
UTHR: 11.8
The chart displays the Price-to-Earnings (P/E) ratio for UTHR, comparing it with other companies in the Biotechnology industry. Currently, UTHR has a P/E ratio of 11.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
2.04.06.08.010.0
UTHR: 1.4
The chart shows the Price/Earnings to Growth (PEG) ratio for UTHR compared to other companies in the Biotechnology industry. UTHR currently has a PEG ratio of 1.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
20.040.060.080.0100.0
UTHR: 4.5
This chart shows the Price-to-Sales (P/S) ratio for UTHR relative to other companies in the Biotechnology industry. Currently, UTHR has a P/S ratio of 4.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
2.04.06.08.010.0
UTHR: 2.1
The chart illustrates the Price-to-Book (P/B) ratio for UTHR in comparison with other companies in the Biotechnology industry. Currently, UTHR has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items